Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PS2 expression in BRCA1-associated breast cancers.

E Charafe-Jauffre1, F Eisinger, M P Mathoulin-Portier

  • 1Department de Pathologie Institut Paoli-Calmettes, Marseille, France.

Anticancer Research
|November 20, 2001
PubMed
Summary

pS2 expression is significantly lower in BRCA1-mutated breast cancers compared to sporadic types. This difference, linked to estrogen receptor status, highlights distinct molecular profiles in BRCA1-associated breast cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Bone marrow transplantation·2017
Same author

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Bone marrow transplantation·2016
Same author

Maintaining professional activity during breast cancer treatment.

European journal of cancer care·2016
Same author

Familial hematological malignancies: ASXL1 gene investigation.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2015
Same author

Prostate cancer screening: contrasting trends.

Cancer causes & control : CCC·2015
Same author

Melanoma risk-takers: fathers and sons.

Journal of the European Academy of Dermatology and Venereology : JEADV·2015

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Estrogen receptor (ER) status influences pS2 expression, a key prognostic factor in breast cancer survival.
  • Breast carcinomas with BRCA1 mutations (BRCA1-BCs) display unique characteristics, particularly concerning ER expression.
  • Understanding pS2 expression differences is crucial for characterizing BRCA1-BCs.

Purpose of the Study:

  • To investigate and compare pS2 expression levels between BRCA1-mutated breast cancers and sporadic breast cancers.
  • To determine if pS2 expression differs significantly based on BRCA1 mutation status.

Main Methods:

  • Immunohistochemistry was employed to assess pS2 expression.
  • The study included 33 BRCA1-BCs and 193 sporadic breast cancer cases.

Related Experiment Videos

  • Analysis considered various parameters, including estrogen receptor (ER) and progesterone receptor (PR) status.

    • Main Results:

    • pS2 expression was significantly lower in BRCA1-BCs (30.3%) compared to sporadic breast cancers (68.9%) (p<0.0001).
    • In BRCA1-BCs, pS2 expression was observed in 4/4 ER-positive cases, while sporadic cancers showed 80.37% pS2 positivity in ER-positive cases.
    • Multivariate analysis revealed pS2 expression correlated with ER status but not with BRCA1 mutation status.

    Conclusions:

    • pS2 expression is significantly different in BRCA1-BCs compared to sporadic breast cancers.
    • pS2 expression correlates with ER status in both BRCA1-BCs and sporadic cancers.
    • BRCA1 mutation status is not an independent predictor of pS2 expression in multivariate analysis.